Literature DB >> 8312579

An evaluation of clinical follow-up in women with early stage breast cancer among physician members of the American Society of Clinical Oncology.

M S Simon1, M Hoff, M Hussein, S Martino, A Walt.   

Abstract

Routine clinical follow-up for distant metastatic disease among women with early stage breast cancer is of uncertain clinical benefit. In order to evaluate current practice patterns, we administered a mailed survey to a stratified random sample of physician members of the American Society of Clinical Oncology (ASCO) (N = 435). The survey assessed the frequency and motivation for ordering follow-up medical tests in asymptomatic postmenopausal women with stage I or II breast cancer. The response rate was 55%, distributed as 39% radiation oncologists, 32% medical oncologists, and 29% surgeons. In the first year after treatment, physicians performed, on average, one physical examination every 3 months, one blood panel (CBC, alkaline phosphatase and liver function tests) every 4 months, and one chest radiograph every 9 months. In addition, 38% of the respondents ordered CEA and 21% ordered CA 15-3 levels, 28% ordered bone scans, and less than 4% ordered CT scans, bone surveys, or bone marrow biopsies in the first year after treatment. A logistic regression analysis controlling for physician age, gender, sub-specialty, practice type, years of experience, number of breast cancer patients treated annually, geographic region, and community size, showed that surgeons were less likely to order blood tests (p < 0.001) and tumor markers (p < 0.0029) than medical oncologists in years 3 and 5 of follow-up. Compared to physicians practicing in the northeast, those from the midwest were less likely to order chest radiographs in year 3 of follow-up (p = 0.0028). Other provider characteristics had no significant effect on test ordering behavior. The results of this survey suggest that relatively uniform practice patterns in regard to the follow-up of postmenopausal women with early stage breast cancer exist among ASCO physicians.

Entities:  

Mesh:

Year:  1993        PMID: 8312579     DOI: 10.1007/bf00665691

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  43 in total

1.  The value of symptom directed evaluation in the surveillance for recurrence of carcinoma of the breast.

Authors:  L D Wagman; R D Sanders; J J Terz; J D Beatty; W A Kokal; D U Riihimaki
Journal:  Surg Gynecol Obstet       Date:  1991-03

2.  An evaluation of bone scans as screening procedures for occult metastases in primary breast cancer.

Authors:  R R Baker; E R Holmes; P O Alderson; N F Khouri; H N Wagner
Journal:  Ann Surg       Date:  1977-09       Impact factor: 12.969

3.  The value of yearly chest X-ray in patients with stage I breast cancer.

Authors:  A Vestergaard; J Herrstedt; H S Thomsen; P Dombernowsky; K Zedeler
Journal:  Eur J Cancer Clin Oncol       Date:  1989-04

4.  Metastatic pattern in recurrent breast cancer. Special reference to intrathoracic recurrences.

Authors:  C Kamby; I Vejborg; B Kristensen; L O Olsen; H T Mouridsen
Journal:  Cancer       Date:  1988-11-15       Impact factor: 6.860

5.  Long-term survival of women with breast cancer.

Authors:  D Brinkley; J L Haybittle
Journal:  Lancet       Date:  1984-05-19       Impact factor: 79.321

6.  The efficacy of bone scanning in the follow-up of patients with operable breast cancer.

Authors:  L Wickerham; B Fisher; W Cronin
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

7.  The value of bone scans in the management of patients with carcinoma of the breast.

Authors:  F E Burkett; E F Scanlon; R M Garces; J D Khandekar
Journal:  Surg Gynecol Obstet       Date:  1979-10

8.  Bone metastases in primary operable breast cancer. The role of a yearly scintigraphy.

Authors:  H S Thomsen; D Rasmussen; O Munck; J O Lund; V Gerhard-Nielsen; T Terkildsen; P Dombernowsky; K W Andersen
Journal:  Eur J Cancer Clin Oncol       Date:  1987-06

9.  First repeated bone scan in the observation of patients with operable breast cancer.

Authors:  A Pedrazzini; R Gelber; M Isley; M Castiglione; A Goldhirsch
Journal:  J Clin Oncol       Date:  1986-03       Impact factor: 44.544

10.  A retrospective study of earliest indicators of recurrence in patients on Eastern Cooperative Oncology Group adjuvant chemotherapy trials for breast cancer. A preliminary report.

Authors:  K J Pandya; E T McFadden; L A Kalish; D C Tormey; S G Taylor; G Falkson
Journal:  Cancer       Date:  1985-01-01       Impact factor: 6.860

View more
  2 in total

1.  Clinical surveillance for early stage breast cancer: an analysis of claims data.

Authors:  M S Simon; M Stano; R K Severson; M S Hoff; D W Smith
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  An analysis of the cost of clinical surveillance after primary therapy for women with early stage invasive breast cancer.

Authors:  M S Simon; M Stano; M Hussein; M Hoff; D Smith
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.